Drug Profile
ALN VSP
Alternative Names: ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Angiogenesis inhibitors; KIF11 protein inhibitors; RNA interference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Liver cancer; Liver metastases
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Liver metastases in Spain (IV, Liposomal)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Liver metastases in USA (IV, Liposomal)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Liver-cancer in Spain (IV, Liposomal)